Confirmed Speakers Scientific Conference (list is updating)

Michel Sadelain, MD, PhD, Director of the Columbia Initiative in Cell Engineering and Therapy (CICET), Director of the Medical Center’s Cancer Cell Therapy Initiative in the Herbert Irving Comprehensive Cancer Center, USA.
Paula Rio, PhD, Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid, Spain.

---

Alessia Cavazza, Ass. Prof., Group Leader, Infection, Immunity & Inflammation Department at University College London's Great Ormond Street Institute of Child Health, England.
Anastasia Conti, Postdoc, Project Leader, San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), Milan, Italy.
André Cohnen, VP and Head of Gene Editing, Bayer Pharmaceuticals, Germany.
Andrew Sewell, Distinguished Research Prof. & Welcome Trust Senior Investigator, Cardiff University School of Medicine, UK.
Ayal Hendel, Principal Investigator and Group Leader, Bar-Ilan University, Israel.
Carla Fuster García, Postdoc, Institute for Transfusion Medicine and Gene Therapy,Universitätsklinikum Freiburg, Germany.
Cecilia Jimenez-Mallebrera, PhD and Research Director, Institut de Recerca Sant Joan de Déu. Hospital Sant Joan de Déu Barcelona and CIBERER, Spain.
Christian Grøndahl, Dr. Med., Co-Founder & CEO, SNIPR Biome, Denmark.
Francisco J. Sánchez-Rivera, PhD, Eisen and Chang Career Development Assistant Professor of Biology, Massachusetts Institute of Technology (MIT); Intramural Faculty, Koch Institute for Integrative Cancer Research; HHMI Hanna H. Gray Fellow, USA.
Giorgio Galli, PhD, Group Leader, Oncology Drug Discovery Biology Unit, Novartis Institute for Biomedical Research, Basel, Switzerland.
Jakob Nilsson, Prof., PhD, Danish Cancer Institute, Copenhagen, Denmark.
Karim Benabdel Lah El Khlanji, Senior Scientist, GENyO Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain, GeneHumdi Action Chair.
Karina Thorn, PhD, Corporate VP and Head of Nucleic Acid Therapies, Novo Nordisk, DK.
Laura Torella, Postdoc, AstraZeneca, Sweden.
Manuel A.F.V. Gonçalves, Dr., Group Leader, Genome Editing, Department of Cell and Chemical biology, Leiden University Medical Center, Leiden, Netherlands.
Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden.
Mathew Garnett, Dr., PhD, Senior Group Leader, Wellcome Sanger Institute & Co-founder of Mosaic Therapeutics, UK.
Nerea Zabaleta, Ass. Prof., Principal Investigator, Next Generation Gene Delivery Technologies Group, University of Navarra (CIMA), Spain.
Özcan Met, PhD, Ass. Prof., Head of Cell Therapy Unit at the National Center for Cancer Immune Therapy (CCIT-DK) at Herlev University Hospital and DTU HealthTech, Denmark.
Patrick Pausch, PhD, Research Prof. and Group Leader, , VU LSC-EMBL Partnership Institute for Genome Editing Technologies, Vilnius, Lithuania.
Peter Haahr, PhD, Ass. Prof, Group leader, Center for Gene Expression, Department of Cellular and Molecular Medicine, University of Copenhagen, Denmark.
Randall Platt, Ass. Prof., Group Leader, Department of Biosystems Science and Engineering, ETH Zurich, Switzerland.
Roberta Esposito, Postdoc, Senior Scientist, Department for BioMedical Research (DBMR), University of Bern, Switzerland.
Sean Semple, Dr., Vice President of Preclinical Research, Acuitas Therapeutics, Canada.
Stephan Kadauke, MD, PhD, University of Pennsylvania School of Medicine and Children’s Hospital of Philadelphia (CHOP), USA.